EU/3/16/1763

Table of contents

About

On 14 October 2016, orphan designation (EU/3/16/1763) was granted by the European Commission to Coté Orphan Consulting UK Limited, United Kingdom, for tadekinig alfa for the treatment of haemophagocytic lymphohistiocytosis.

The sponsorship was transferred to Quintiles Ireland Limited, Ireland, in March 2018.

In May 2018 the sponsor, Quintiles Ireland Limited changed name to IQVIA RDS Ireland Limited.

The sponsorship was transferred to YES Pharmaceutical Development Services GmbH in February 2021.

Key facts

Active substance
Tadekinig alfa
Disease / condition
Treatment of haemophagocytic lymphohistiocytosis
Date of first decision
14/10/2016
Outcome
Positive
EU designation number
EU/3/16/1763

Sponsor's contact details

YES Pharmaceutical Development Services GmbH
Bahnstrasse 42-46
61381 Friedrichsdorf
Hassia
Germany
Tel: +49 6172 764 64 65
E-mail: Gregory.huber@ab2bio.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating